Inflammatory/infectious cutaneous side effects of biological drugs in patients with psoriasis: A general review with personal data

F. Rongioletti, M. Burlando, A. Parodi

Research output: Contribution to journalArticlepeer-review

Abstract

In recent years, the use of biologic drugs has greatly changed the therapy of psoriasis and psoriatic arthritis, but they have some adverse effects. In particular, skin lesions induced by anti-tumor necrosis factor (TNF) and anti-interleukin (IL) 12/23 drug (ustekinumab) have been reported with an increased incidence, highlighting the importance of the skin as a major target of the side effects of these drugs. There is a wide spectrum of skin lesions of different morphology and etiology that includes skin lesions directly related to drug administration, the development of cutaneous immune-mediated conditions and cutaneous infections. The aim of this review is to revisit the literature data on inflammatory/infectious skin adverse effects of biologies both anti-TNF-α inhibitors and anti-IL 12/23 antagonists and to report and update our personal data on inflammatory/infectious side effects in patients with psoriasis/psoriatic arthritis treated with biologics.

Original languageEnglish
Pages (from-to)311-316
Number of pages6
JournalGiornale Italiano di Dermatologia e Venereologia
Volume149
Issue number3
Publication statusPublished - 2014

Keywords

  • Biological products
  • Drug-related side effects and adverse reactions
  • Psoriasis

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'Inflammatory/infectious cutaneous side effects of biological drugs in patients with psoriasis: A general review with personal data'. Together they form a unique fingerprint.

Cite this